Influenza
Conditions
Keywords
Multimeric, Vaccine, Influenza, elderly, phase 1/2, safety, efficacy, tolerability, reactogenicity, Montanide, hemagglutinin inhibition, HAI, TIV
Brief summary
This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.
Detailed description
This is a Phase I/II single-center, randomized, placebo-controlled, single-blind, dose-escalation, double-dose administration study comprising two dosing cohorts (Cohort 1: 250 mcg M-001 per injection and Cohort 2: 500 mcg M-001 per injection) with 20 subjects in each cohort receiving either adjuvanted or non-adjuvanted formulations. The adjuvant used was Montanide ISA VG51. Cohort 3 with 20 subjects was administered placebo. After priming with M-001 or placebo, all participants were administered a boost of a conventional trivalent vaccine on day 42. There was a minimum of 10 days interval between last dosing of the first injection to the last subject of the 250 μg cohort (Cohort 1) and first dosing of the first subject injection with 500 µg cohort (Cohort 2). For each subject, the second injection was performed 21+2 days after his/her first injection, provided they were deemed fit to be dosed by a study physician. The DSMB reviewed the safety data obtained from cohorts 1 and 2 before approving their second injection and before dose escalation.
Interventions
BIOLOGICALMultimeric-001 250 mcg
Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
BIOLOGICALAdjuvanted Multimeric-001 250mcg
Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
BIOLOGICALPlacebo
Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
BIOLOGICALAdjuvant: Montonide isa 51 VG
Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
BIOLOGICALMultimeric-001 500 mcg
Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
BIOLOGICALAdjuvanted Multimeric-001 500mcg
Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
BIOLOGICALTIV
Injection of the conventional flu vaccine: Vaxigrip to all study participants.
Sponsors
BiondVax Pharmaceuticals ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
55 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Males and females between the age of 55 and 75 years (inclusive): * Healthy or treated for any or all of the following conditions: * Hypertension, under control with standard medications * Hyperlipidemia, medically treated * Subjects who provide written informed consent to participate in the study. * Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study. * Haematology, chemistry and urinalysis values with no clinical significance or do not reflect a medical condition which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study. * Female of childbearing age must agree to use an acceptable method of contraception and male subjects should use a condom throughout the study period (including the follow up- where applicable) if female partner is not using an effective contraceptive method.
Exclusion criteria
* Known history of significant medical disorder, which in the investigator's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study. * Renal dysfunction. * COPD. * Chronic cardiovascular system disorders (except hypertension adequately controlled by standard medications). * Asthma * Diabetes mellitus. * Subjects with known Guillain Barré Syndrome in the past. * Two or more hospitalizations within the last year prior to screening visit. * Bleeding disorders including hemophilia or thrombocytopenia, or treatment with anticoagulant therapy (risk of bleeding with intramuscular injection). * Immunocompromised patients and those receiving concomitant immunosuppressive therapy; or other immune modulating drugs including chronic steroid treatment. * Subjects who have been immunized with anti-influenza vaccine or infected by influenza virus within eight months prior to the screening visit. * Administration of any vaccine 30 days before the screening visit. * Known hypersensitivity to previous influenza vaccination. * Use of an influenza antiviral medication within 4 weeks of vaccination. * Known hypersensitivity and/or allergy to any drug or vaccine. * Known hypersensitivity to egg proteins (eggs or egg products), chicken proteins, or any of the vaccine components, in particular, neomycin, formaldehyde, and octoxinol 9, * Known history of drug or alcohol abuse. * Any clinically significant abnormality upon physical examination or in the clinical laboratory tests at screening visit which, according to the physician's judgment, might confound the results of the study or pose additional risk to the subject by participation in the study. * Increased liver enzymes more than 2.5 times above the upper reference level. * Positive serology for HIV, HCV antibody or HBsAg. * Any acute medical situation (e.g. acute infection, ongoing flu symptoms) with or without fever within 48 hours of vaccination, which is considered of significance by the Principal Investigator. * Pregnant or lactating women at entry to study and those who are unwilling to agree to continue to use acceptable methods of contraception for two months after completion of the study (if applicable). * Positive blood pregnancy test on screening. * Subjects who participated in another clinical study within 30 days prior to study entry. * Subjects who are non-cooperative or unwilling to sign consent form.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the safety, local and systemic tolerability and reactogenicity of Multimeric-001 vaccine when administered intramuscularly twice to elderly male and female subjects, using chemistry, CBC, fibrinogen, and urinalysis measurements. | From day 0 until termination visit | The Multimeric-001 vaccine exhibits a positive safety profile. The number of subjects reporting adverse events (AEs) after treatment with active vaccines was similar to respective placebo cohorts. Overall AE frequencies for each active group were similar to those of placebo counterparts. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To characterize the immune response | 21 days after second immunization with M-001 and 21 days after TIV boost | The Multimeric-001 vaccine induces both humoral and cellular immune responses, confirming previous findings in younger adults. |
| To monitor cellular immune responses | 21 days after second M-001 immunization | PBMC proliferation associated with IFN gamma secretion was detected after prime immunizations following in vitro exposure of the cells to M-001 or influenza viruses. |
| To obtain preliminary data on the contribution of the adjuvant | 21 days after second M-001 immunization and 21 days after TIV boost | Adjuvant had an impact on anti-M-001 IgG levels but not on HAI antibody levels. |
| To obtain preliminary evidence about the efficacy of M-001 as a primer | 21 days after TIV boost | The prime-boost regimen elicits HAI immune responses, which enables assessment of an accepted surrogate marker considered to correlate with influenza vaccine activity.Priming with M-001 before a TIV boost resulted in a greater proportion of subjects seroconverted to TIV and non-TIV strains as compared to subjects given TIV alone. |
Countries
Israel
Outcome results
None listed